<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) constitutes most primary central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PCNSL), whereas T-cell, low-grade and Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) are rarely encountered </plain></SENT>
<SENT sid="1" pm="."><plain>Due to the paucity of cases, little is known about the clinical features and treatment outcomes of PCNSL other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The objective of this study was to describe the clinical characteristics and outcomes for patients with PCNSL other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Fifteen patients, newly diagnosed with PCNSLs other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> between 2000 and 2010, were included </plain></SENT>
<SENT sid="4" pm="."><plain>The male to female ratio was 0.67:1 with a median age of diagnosis of 31 years (range 18-59) </plain></SENT>
<SENT sid="5" pm="."><plain>Pathologic distributions were as follows: peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e>; n=7), marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e>; n=1), lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (LPL; n=2), Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=1), other unspecified (T-cell lineage, n=2; B-cell lineage, n=2) </plain></SENT>
<SENT sid="6" pm="."><plain>Thirteen patients (87%) showed Eastern Cooperative <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group performance score (ECOG PS) 1-2 </plain></SENT>
<SENT sid="7" pm="."><plain>The remaining two were one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PTCL</z:e> patient and one Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patient </plain></SENT>
<SENT sid="8" pm="."><plain>Of the nine patients with T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, five (56%) had multifocal lesions, and one (20%) with LPL of the five patients with B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed a single lesion </plain></SENT>
<SENT sid="9" pm="."><plain>Leptomeningeal lymphomatosis was identified in two patients (one with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and one with unspecified B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="10" pm="."><plain>Two patients (22%) with T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> died 7.7 and 23.3 months later, respectively, due to disease progression, despite <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-MTX-based therapy </plain></SENT>
<SENT sid="11" pm="."><plain>Six patients with T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (6/9, 66.7%) and four patients with low-grade B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (4/5, 80%) achieved complete response and have survived without relapse (Table 3) </plain></SENT>
<SENT sid="12" pm="."><plain>One patient with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed poor clinical features with ECOG PS 3, deep structure, multifocal, and leptomeningeal lymphomatosis, and died 7.6 months after the initiation of treatment </plain></SENT>
<SENT sid="13" pm="."><plain>In comparison with previously reported <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCLs</z:e> (median OS 6.4 years, 95% CI 3.7-9.1 years), T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> showed equivocal or favorable clinical outcomes and low-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, such as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e> and LPL, had a good prognosis </plain></SENT>
<SENT sid="14" pm="."><plain>However, primary <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> presented poor clinical outcomes and showed a comparatively aggressive clinical course </plain></SENT>
<SENT sid="15" pm="."><plain>In conclusion, primary <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> other than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> occurred more in younger patients and showed a generally good prognosis, except for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="16" pm="."><plain>Further research on treatment strategies for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is needed </plain></SENT>
</text></document>